Recent developments in olfactory neuroblastoma research.

Curr Opin Otolaryngol Head Neck Surg

Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine.

Published: February 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose Of Review: Olfactory neuroblastoma (ONB) is a rare malignancy originating from olfactory neuroepithelial cells. Given its uncommon nature and complex clinical presentation, this comprehensive review highlights recent findings and treatment approaches for advancing clinical practice and research.

Recent Findings: Recent literature emphasizes significant advancements in the genomic profiling and molecular classification of ONB. Emerging targeted therapies include somatostatin analogs and programmed death-ligand 1 (PD-L1) inhibitors. In addition, the development of genetically engineered mouse models has provided valuable platforms for testing new treatment strategies, revealing similarities between ONB and small cell lung cancer, which may inform future therapeutic approaches.

Summary: These findings have profound implications on clinical practice. Improved diagnostic accuracy through advanced imaging and genomic profiling in addition to identifying specific mutations for targeted therapy can lead to personalized treatments of patients with ONB. Developments in genetically engineered mouse models and multiinstitutional collaborative efforts are vital for advancing research and standardizing molecular testing. The integration of advanced imaging techniques, genomic profiling, and targeted therapies holds promise for improving patient outcomes and understanding this rare malignancy.

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOO.0000000000001027DOI Listing

Publication Analysis

Top Keywords

genomic profiling
12
olfactory neuroblastoma
8
rare malignancy
8
clinical practice
8
targeted therapies
8
genetically engineered
8
engineered mouse
8
mouse models
8
advanced imaging
8
developments olfactory
4

Similar Publications

Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder characterized by systemic inflammation and lymphadenopathy. Two major clinical subtypes, idiopathic plasmacytic lymphadenopathy (iMCD-IPL) and iMCD with thrombocytopenia, anasarca, fever, renal dysfunction/reticulin fibrosis, and organomegaly (iMCD-TAFRO), exhibit distinct pathophysiologic mechanisms. While interleukin-6 (IL-6) is known to be elevated in iMCD, the differences in IL-6 production sources between subtypes remain unclear.

View Article and Find Full Text PDF

Objective: Systemic sclerosis (SSc) is a complex autoimmune connective tissue disease. Genetic factors may play a pivotal role in determining susceptibility to these disorders. HLA associations with SSc, especially HLA class II, were investigated in different populations but not in Tunisia.

View Article and Find Full Text PDF

Purpose: Next-generation sequencing (NGS) has revolutionized cancer treatment by enabling comprehensive cancer genomic profiling (CGP) to guide genotype-directed therapies. While several prospective trials have demonstrated varying outcomes with CGP in patients with advanced solid tumors, its clinical utility in colorectal cancer (CRC) remains to be evaluated.

Methods: We conducted a prospective observational study of CGP in our hospital between September 2019 and March 2024.

View Article and Find Full Text PDF

Inflammatory gene expression profile of oral plasmablastic lymphoma.

Virchows Arch

September 2025

Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais, Minas Gerais, Av. Antônio Carlos, Pampulha, Belo Horizonte, 31270-901, Brazil.

Plasmablastic lymphoma (PBL) is a rare and aggressive non-Hodgkin lymphoma with a poor prognosis and short survival rates. It is classified as a large B-cell lymphoma subtype, but carries a plasmacytic immunophenotype. Therefore, PBL has pathogenetic overlaps with diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) and plasma cell neoplasms (PCNs).

View Article and Find Full Text PDF

Vascular sites have distinct susceptibility to atherosclerosis and aneurysm, yet the epigenomic and transcriptomic underpinning of vascular site-specific disease risk is largely unknown. Here, we performed single-cell chromatin accessibility (scATACseq) and gene expression profiling (scRNAseq) of mouse vascular tissue from three vascular sites. Through interrogation of epigenomic enhancers and gene regulatory networks, we discovered key regulatory enhancers to not only be cell type, but vascular site-specific.

View Article and Find Full Text PDF